Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMEDLXJ)

Drug Name	ORBOFIBAN DMEDLXJ
Synonyms	Orbofiban; UNII-FGJ53JS7PT; 163250-90-6; FGJ53JS7PT; CHEMBL64706; SC-57099B; Orbofiban [INN]; AC1L435J; SCHEMBL7854981; DTXSID20167543; ZINC3951736; BDBM50092109; AKOS022181223; AJ-47472; ethyl 3-[[(3S)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate; 3-{(S)-3-[1-(4-Carbamimidoyl-phenyl)-2-oxo-pyrrolidin-3-yl]-ureido}-propionic acid ethyl ester; beta-Alanine, N-((((3S)-1-(4-(aminoiminomethyl)phenyl)-2-oxo-3- pyrrolidinyl)amino)carbonyl)-, ethyl ester
Drug Type	Small molecular drug
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Cardiovascular disease	DIS2IQDX	BA00-BE2Z	Discontinued in Phase 3	[1]
Angina pectoris	DISCLMC4	BA40	Discontinued in Phase 3	[2]
------------------------------------------------------------------------------------

References

1	Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007819)